Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP, Chf GL Pdt Str Ofcr | April 15, 2026 | April 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date April 15, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,713 |
Ending reported balance
After 2026-04-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-15 · Exercise / conversion · Acquired 12,226 · Balance 28,615 F1: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Row 2 · 2026-04-16 · Sale · Disposed 4,902 · Balance 23,713 F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.06 to $75.26 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 74,402 |
Reported balance
After 2026-04-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-15 · Exercise / conversion · Disposed 12,226 · Balance 74,402 F4: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
F2: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.06 to $75.26 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F5: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AKCEA THERAPEUTICS, INC.
Report date October 12, 2020 · Filed October 13, 2020
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 1
1 source rowRow 1 · 2020-10-12 · Other · Disposed 52,012 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-06-04 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-12 · Disposition to issuer · Disposed 143,374 · Balance 0 F1: This option, which provided that 1/4th of the shares would vest one year after May 15, 2017 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $851,641.56, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-06-04 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-12 · Disposition to issuer · Disposed 32,751 · Balance 0 F2: This option, which provided that 1/4th of the shares would vest one year after May 15, 2017 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $194,540.94, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.38 · Expires 2028-01-01 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-12 · Disposition to issuer · Disposed 299 · Balance 0 F3: This option, which provided that 1/4th of the shares would vest one year after January 2, 2018 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $230.23, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.38 · Expires 2028-01-01 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-12 · Disposition to issuer · Disposed 13,701 · Balance 0 F4: This option, which provided that 1/4th of the shares would vest one year after January 2, 2018 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $10,549.77, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2030-03-18 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-12 · Disposition to issuer · Disposed 34,200 · Balance 0 F5: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $184,338.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which provided that 1/4th of the shares would vest one year after May 15, 2017 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $851,641.56, representing the difference between the exercise price of the option and the acquisition price of $18.15.
F2: This option, which provided that 1/4th of the shares would vest one year after May 15, 2017 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $194,540.94, representing the difference between the exercise price of the option and the acquisition price of $18.15.
F3: This option, which provided that 1/4th of the shares would vest one year after January 2, 2018 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $230.23, representing the difference between the exercise price of the option and the acquisition price of $18.15.
F4: This option, which provided that 1/4th of the shares would vest one year after January 2, 2018 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $10,549.77, representing the difference between the exercise price of the option and the acquisition price of $18.15.
F5: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $184,338.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 17, 2026 23:19 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,902 | $75.17 | $368,488.24 |
DisclosureSEC source: 0000874015-26-000171 · edgardoc.xml · nonDerivative · entry 2 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,713 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.06 to $75.26 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 12,226 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000171 · edgardoc.xml · derivative · entry 3 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,402 Underlying: Common Stock · 12,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 23:19 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000171 · edgardoc.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 32,602 | $0.00 Strike: $46.10 | $0.00 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · derivative · entry 6 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,601 Underlying: Common Stock · 32,602 shares Expires 2034-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,675 | $0.00 Strike: $34.69 | $0.00 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · derivative · entry 5 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,025 Underlying: Common Stock · 4,675 shares Expires 2035-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,675 | $34.69 | $162,175.75 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · nonDerivative · entry 4 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 16,086 | $76.30 | $1,227,361.80 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · nonDerivative · entry 3 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,714 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 21,191 | $75.50 | $1,599,962.88 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · nonDerivative · entry 2 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,800 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.005 to $76.00 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 32,602 | $46.10 | $1,502,952.20 |
DisclosureSEC source: 0000874015-26-000142 · edgardoc.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,823 | $75.96 | $138,475.08 |
DisclosureSEC source: 0000874015-26-000066 · edgardoc.xml · nonDerivative · entry 2 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,389 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.96 to $75.97 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 7,013 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000066 · edgardoc.xml · derivative · entry 5 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,664 Underlying: Common Stock · 7,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 9,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000066 · edgardoc.xml · derivative · entry 4 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,725 Underlying: Common Stock · 9,675 shares Expires not disclosed F6 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantPerformance Restricted Stock Units · Derivative | 25,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000066 · edgardoc.xml · derivative · entry 3 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 25,800 shares Expires not disclosed F4 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F5 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. F5 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,013 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000066 · edgardoc.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,350 | $0.00 Strike: $79.67 | $0.00 |
DisclosureSEC source: 0000874015-26-000027 · edgardoc.xml · derivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,350 Underlying: Common Stock · 19,350 shares Expires 2036-01-01 F1 · derivative.exercise_date: Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| April 16, 2025 Filed Apr 17, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,016 | $28.36 | $85,533.76 |
DisclosureSEC source: 0000874015-25-000119 · edgardoc.xml · nonDerivative · entry 2 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,199 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.35 to $28.37 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 12,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000119 · edgardoc.xml · derivative · entry 3 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,677 Underlying: Common Stock · 12,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000119 · edgardoc.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 28,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000061 · edgardoc.xml · derivative · entry 2 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,050 Underlying: Common Stock · 28,050 shares Expires not disclosed F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2025 Filed Jan 18, 2025 00:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantPerformance Restricted Stock Units · Derivative | 18,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000061 · edgardoc.xml · derivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires not disclosed F1 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. F2 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 18,700 | $0.00 Strike: $34.69 | $0.00 |
DisclosureSEC source: 0000874015-25-000027 · edgardoc.xml · derivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2035-01-01 F1 · derivative.exercise_date: Grant on 01/02/2025 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2020 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2025. 25% of the shares subject to the option will vest and become exercisable on 01/02/2026. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| February 26, 2024 Filed Mar 13, 2024 21:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 65,203 | $0.00 Strike: $46.10 | $0.00 |
DisclosureSEC source: 0000874015-24-000133 · edgardoc.xml · derivative · entry 1 Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,203 Underlying: Common Stock · 65,203 shares Expires 2034-02-25 F1 · derivative.exercise_date: Grant on 02/26/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2020 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 02/26/2024. 25% of the shares subject to the option will vest and become exercisable on 02/26/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 34,200 | $5.39 Strike: $12.76 | $184,338.00 |
DisclosureSEC source: 0001209191-20-054616 · doc4.xml · derivative · entry 6 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,200 shares Expires 2030-03-18 F5 · derivative.exercise_date: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $184,338.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 13,701 | $0.77 Strike: $17.38 | $10,549.77 |
DisclosureSEC source: 0001209191-20-054616 · doc4.xml · derivative · entry 5 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,701 shares Expires 2028-01-01 F4 · derivative.exercise_date: This option, which provided that 1/4th of the shares would vest one year after January 2, 2018 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $10,549.77, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 299 | $0.77 Strike: $17.38 | $230.23 |
DisclosureSEC source: 0001209191-20-054616 · doc4.xml · derivative · entry 4 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 299 shares Expires 2028-01-01 F3 · derivative.exercise_date: This option, which provided that 1/4th of the shares would vest one year after January 2, 2018 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $230.23, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 32,751 | $5.94 Strike: $12.21 | $194,540.94 |
DisclosureSEC source: 0001209191-20-054616 · doc4.xml · derivative · entry 3 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,751 shares Expires 2027-06-04 F2 · derivative.exercise_date: This option, which provided that 1/4th of the shares would vest one year after May 15, 2017 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $194,540.94, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 143,374 | $5.94 Strike: $12.21 | $851,641.56 |
DisclosureSEC source: 0001209191-20-054616 · doc4.xml · derivative · entry 2 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 143,374 shares Expires 2027-06-04 F1 · derivative.exercise_date: This option, which provided that 1/4th of the shares would vest one year after May 15, 2017 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $851,641.56, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:59 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | OtherCommon Stock | 52,012 | $18.15 | $944,017.80 |
DisclosureSEC source: 0001209191-20-054616 · doc4.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 16:21 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | SaleCommon Stock | 720 | $18.12 | $13,046.40 |
DisclosureSEC source: 0001209191-20-051891 · doc4.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,012 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on September 19, 2019. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 16:43 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | SaleCommon Stock | 779 | $11.75 | $9,153.48 |
DisclosureSEC source: 0001209191-20-021122 · doc4.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,732 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on September 19, 2019. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:34 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 34,200 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-20-020643 · doc4.xml · derivative · entry 2 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,200 Underlying: Common Stock · 34,200 shares Expires 2030-03-18 F2 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after March 19, 2020;1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:34 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantCommon Stock | 16,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020643 · doc4.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,511 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| October 21, 2019 Filed Oct 23, 2019 16:21 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $18.94 | $0.00 |
DisclosureSEC source: 0001209191-19-053841 · doc4.xml · derivative · entry 2 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-10-20 F1 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after October 21, 2019;1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| October 21, 2019 Filed Oct 23, 2019 16:21 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053841 · doc4.xml · nonDerivative · entry 1 Jenne Kyle · CIK 0001791857 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,711 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.